An Act to amend the Code of Virginia by adding in Title 59.1 a chapter numbered 22.25, consisting of a section numbered 59.1-284.46, relating to Pharmaceutical Substance Manufacturing Grant Fund.
HB1076 creates the Pharmaceutical Substance Manufacturing Grant Fund in the state treasury and authorizes grants to a single qualifying pharmaceutical manufacturing project in Virginia. The bill defines a “qualified company” as one engaged in manufacturing pharmaceutical substances that, within the specified timeframe, is expected to make at least a $4 billion capital investment and create and maintain at least 500 new full-time jobs. It also defines “eligible locality” as Albemarle County, making the program geographically targeted to that locality.
The grant program is structured as a nonreverting special fund and allows grant payments totaling up to $191,255,000. The money may be used for construction and development of the facility or any other lawful purpose. Eligibility and payment are tied to a memorandum of understanding among the company, the Commonwealth, and the Virginia Economic Development Partnership Authority, which must set performance requirements for capital investment and job creation. The bill also specifies detailed definitions for capital investment, facility, and new full-time job, including a minimum average annual wage of $160,750 and standard fringe benefits.
The bill adds a new chapter to Title 59.1 of the Code of Virginia establishing a state economic development incentive program for pharmaceutical substance manufacturing. It creates a special nonreverting fund in the state treasury, directs how appropriations and interest are handled, and authorizes the State Treasurer and Comptroller to administer disbursements. In practical terms, it commits state law to a long-term grant mechanism that can support a large-scale industrial project in Albemarle County, conditioned on investment and employment benchmarks.
The available record shows no committee transcript or recorded vote breakdown, so there is no documented debate in the materials provided. Based on the bill’s structure, the measure appears to have been treated as an economic development incentive aimed at attracting a major pharmaceutical manufacturing investment to Virginia. Its enactment as Chapter 808 indicates it ultimately received sufficient support to become law.
No specific points of contention are documented in the provided transcripts or votes. However, the bill’s design suggests the likely areas of concern would be the size of the public subsidy, the concentration of benefits in a single locality, and the high wage and investment thresholds required to qualify. Potential supporters would be economic development officials and local stakeholders in Albemarle County, while critics might question the use of state funds for a single company and the scale of the grant relative to public return.